EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH

View source ↗

Summary

Authorised status for Tecentriq (atezolizumab) by Roche Registration GmbH across multiple cancer indications in the European market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Non-small Cell Lung Carcinoma
• Small Cell Lung Carcinoma
• Transitional Cell Carcinoma
• Urologic Neoplasms

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma. MAH: Roche Registration GmbH. Decision date: 26/03/2026